Predictive Oncology Reveals New Appointments to Leadership Team and Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 14 2025
0mins
Should l Buy ?
Leadership Changes: Predictive Oncology has expanded its leadership team and Board of Directors to enhance its digital asset treasury strategy focused on the Aethir (ATH) token.
New Appointments: Shawn Matthews and Thomas McLaughlin from DNA Holdings Venture have joined the Board and leadership team, respectively, while Sara Turken has been appointed as the new General Counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
